DIRS.INFO The most relevant business & tech news

☆ China should set aside politics and look at Covid jab imports, world's largest vaccine maker says
▼ + stars: | 2023-01-16 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

China needs to move past political considerations and look at importing Covid-19 jabs to end the pandemic globally, according to the chief executive of the world's latest vaccine manufacturer. The main Covid vaccines approved for use in China are from Sinovac and Sinopharm. These jabs are less effective against the Omicron variant than are other mRNA vaccines, such as Pfizer and BioNTech's, several studies have found. Poonawalla said China's pandemic reaction of 2020 — which included building hospitals and infrastructure and taking precautions — showed that Beijing could respond rapidly. He stressed China's decision not to import vaccines from the U.S., India and elsewhere, which have been "very effective."

☆ How this millennial CEO steered the world's largest vaccine maker during the pandemic
▼ + stars: | 2022-12-16 | by ( Olivia Choo | ) www.cnbc.com time to read: +6 min

Adar Poonawalla became the CEO of the world's largest vaccine manufacturer, Serum Institute of India, when he was 30 years old. | Bloomberg | Getty ImagesAdar Poonawalla became the CEO of the world's largest vaccine manufacturer, Serum Institute of India, when he was 30 years old. Today, it is the world's largest vaccine manufacturer — by number of doses produced and sold globally. In 1966, at the age of 25, the elder Poonawalla embarked on a journey to set up the Serum Institute of India. Vaccine production at the Serum Institute of India pharmaceutical plant in Pune, Maharashtra, India.

☆ These defensive stocks are looking more attractive in this topsy-turvy market
▼ + stars: | 2022-11-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

We are talking about stocks that offer defensive growth and do even better if the economy slows down. (DHR) Even Linde (LIN) has some defensive growth attributes, but the stock just had a huge move and we are looking for a little more of a pullback. Our preference is still with stocks that offer defensive growth. We understand buying defensive growth today means you aren't catching the bottom, but bottom fishing is often called an expensive hobby for a reason. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ How a horse breeder launched the world's largest vaccine manufacturer
▼ + stars: | 2022-11-21 | by ( Tanvir Gill | ) www.cnbc.com time to read: +1 min

From its humble beginnings as a horse breeding farm in India to becoming the world's largest vaccine manufacturer, Serum Institute of India has undergone rapid growth throughout the decades to reach its exceptional status. The company faced various challenges from getting permits and licenses to not being able to meet the global demand. But today, it is estimated that more than half the children in the world have been administered with their vaccine. After Adar Poonawalla became the CEO in 2011, he noticed the company did not have enough capacity to meet the growing global demand, leading him to invest more in capacity. As the world learns to live with Covid, Serum Institute also has plans to expand its vaccination portfolio and into the Western markets.

☆ Procter & Gamble gets a price target trim, but is poised for faster growth as inflation cools
▼ + stars: | 2022-10-19 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

More importantly, it maintained its global market share, accelerated productivity savings and improved supply chain efficiencies. Fabric and home care sales of $7.08 billion, up 8% organic (versus a 6% estimate), was shy of the $7.13 billion expected. Baby, feminine and family care sales of $4.93 billion, up 6% organic (versus a 4% estimate), exceeded the $4.85 billion consensus. Feminine care organic sales were up double digits, with growth in all regions, driven by price increases and a positive geographic mix. However, the gains were partially offset by lower market volumes and soft market share.

☆ Serum Institute of India discusses vaccine distribution in the U.S. and Europe
▼ + stars: | 2022-09-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSerum Institute of India discusses vaccine distribution in the U.S. and EuropeAdar Poonawalla of the Serum Institute of India says the United States has shown "quite a bit of interest" in its vaccine.

The AstraZeneca vaccine received approval from UK regulators in December 2020, and Poonawalla became a household name in India. India's Covid-19 tsunamiBut Poonawalla's plans soon went awry when a second wave of Covid-19 hit India in the spring. But by January 2021, the company had a stockpile of just 70 million doses . SII also says that it has increased its production to 220 million doses a month as of October. SII is also expanding its partnerships, having signed a deal with American biotech firm Novavax to manufacture its Covid-19 vaccine, which is awaiting regulatory approvals.

''Cinci persoane au murit'' în incendiu, a declarat pentru presă primarul oraşului Pune, Murlidhar Mohol, iar directorul general al companiei, Adar Poonawala, a prezentat ''condoleanţe'' familiilor victimelor pe contul său de Twitter. Serum Institute se pregăteşte să producă de asemenea un vaccin dezvoltat de compania americană Novavax. incendiul declanşat la Serum / Sursa:Sursa:agerpresCu toate acestea, potrivit canalelor de televiziune, incendiul a izbucnit la un sit în construcţie, departe de instalaţiile de fabricare a vaccinurilor. Nu avem alte informaţii cu privire la amploarea incendiului sau dacă cineva este în pericol", a declarat pentru AFP un oficial al serviciului local de pompieri. "Echipaje de poliţie au ajuns la faţa locului", a declarat pentru AFP poliţia din Pune, fără a oferi alte detalii.

Organizations: Universitatea Oxford, Serum, Novavax Locations: India

☆ Încă o țară intră în cursa pentru vaccinuri împotriva COVID-19
▼ + stars: | 2020-12-10 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +2 min

Companiile indiene urmează să producă opt vaccinuri mai accesibile, concepute pentru a combate COVID-19, inclusiv Covishield-ul AstraZeneca, numit „vaccinul pentru lumea de aici” de către dezvoltatorii săi, relatează Reuters, citat de libertatea.ro. „Există multe vaccinuri care se produc în țări din întreaga lume, dar există o singură națiune care are capacitatea de a produce cantități suficiente pentru a satisface cerințele cetățenilor din fiecare țară, și asta este India”, a declarat ambasadorul Australiei în India, Barry O’Farrell, după ce a vizitat fabricile de vaccinuri din India împreună cu mulți alți diplomați. Între timp, ambalatorul farmaceutic Schott Kaisha intensifică producția de flacoane de vaccin, iar DHL al Deutsche Post află cum să distribuie cel mai bine dozele în țară și în întreaga lume. Aici, mașinile automate umplu și sigilează mii de flacoane cu doze de la AstraZeneca în fiecare oră înainte de a fi mutate într-o cameră frigorifică vastă, cu tavan înalt. Cu aproape 10 milioane de infecții, cel de-al doilea stat afectat de COVID-19 din lume după Statele Unite, guvernul Indiei este probabil să comande o mare parte din vaccinuri pentru 1,3 miliarde de oameni.

Persons: Barry O’Farrell, . SII, Schott Organizations: libertatea.ro, Pfizer Inc, Serum, DHL, Deutsche Locations: India, Moderna, Australiei, Statele Unite, Indiei

Search resuls for: "Adar"

9 mentions found